CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002985:Clinical Protocols; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid